No.10-32

June 23, 2010
Eisai Co., Ltd.

EISAI'S INVESTIGATIONAL ANTICANCER AGENT ERIBULIN MESYLATE (E7389) RECEIVES PRIORITY REVIEW STATUS IN JAPAN

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) granted priority review status on May 18, 2010 to the Marketing Authorization Application submitted by the Company for eribulin mesylate (“eribulin,” also known as E7389) for the treatment of inoperable or recurrent breast cancer. Eribulin is an investigational anticancer agent discovered and developed by Eisai.

Eisai submitted simultaneous regulatory applications for approval of eribulin to the health authorities in Japan, the United States and the European Union (EU) on March 30, 2010. The Company also submitted regulatory applications to the health authorities in Switzerland and Singapore in July 2009. On May 28, 2010 (U.S. Eastern Standard Time), eribulin was granted priority review status in the United States by the

Eisai defines oncology as a therapeutic area of focus and is committed to the development of novel anticancer agents such as eribulin and treatments for supportive care. Through these efforts, Eisai will make further contributions to addressing the diversified needs of and increasing the benefits provided to